- TheStreet.com•2 hours ago
The chances of the french drugs company muscling in on JNJ's talks with Actelion are slim based on Sanofi's cost of capital vs returns from a possible deal.
- Motley Fool•4 hours ago
While attempting to offset biosimilar competition on their best-selling drugs, J&J and Sanofi could be making a big mistake by chasing Actelion.
JNJ.BA : Summary for JOHNSON & JOHNSON CEDEAR EACH R - Yahoo Finance
Johnson & Johnson (JNJ.BA)
Buenos Aires - Buenos Aires Delayed Price. Currency in ARS
Add to watchlist
|Day's Range||350.00 - 360.00|
|52 Week Range||275.50 - 400.00|
|PE Ratio (TTM)||61.44|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|